Inhibition by gomisin C (a lignan from Schizandra chinensis) of the respiratory burst of rat neutrophils.
1. The possible mechanisms of action of the inhibitory effect of gomisin C on the respiratory burst of rat neutrophils in vitro was investigated. 2. The peptide formyl-Met-Leu-Phe (FMLP) induced superoxide anion (O2-) formation and O2 consumption, which was inhibited by gomisin C in a concentration-dependent manner (IC50 21.5 +/- 4.2 micrograms ml-1 for O2- formation). Gomisin C also suppressed O2- formation and consumption at low concentrations of phorbol myristate acetate (PMA) with an IC50 value of 26.9 +/- 2.1 micrograms ml-1 for O2- formation. However, gomisin C did not affect the responses induced by a high concentration of PMA. 3. Gomisin C had no effect on O2- generation and uric acid formation in the xanthine-xanthine oxidase system, and failed to alter O2- generation during dihydroxyfumaric acid (DHF) autoxidation, indicating that it does not scavenge superoxide. 4. Like trifluoperazine (TFP), gomisin C attenuated the activity of PMA-activated neutrophil particulate NADPH oxidase in a concentration-dependent manner. 5. Gomisin C reduced the elevations of cytosolic free Ca2+ in neutrophils stimulated by FMLP in the presence or absence of EDTA. Cyclopiazonic acid (CPA) induced the release of Ca2+ from intracellular stores and this was also reduced by gomisin C. However, the Ca2+ influx pathway activated by CPA was not affected by gomisin C. 6. The cellular cyclic AMP level was markedly increased by forskolin, but not by gomisin C. Moreover, the inositol phosphate levels in FMLP-activated neutrophils were not affected by gomisin C. 7. These results show that the inhibitory action of gomisin C on the respiratory burst is not mediated by changes in cellular cyclic AMP or in inositol phosphates, or by scavenging O2- released from neutrophils, but may be mediated partly by the suppression of NADPH oxidase and partly by the decrease of cytosolic Ca2+ released from an agonist-sensitive intracellular store.
Department of Medical Research, Taichung Veterans General Hospital, Taiwan.
J P
JP
Wang
S L
SL
Raung
M F
MF
Hsu
C C
CC
Chen
D000818:Animals; D002118:Calcium / Q000378:metabolism; D000242:Cyclic AMP / Q000032:analysis; D034242:Cyclooctanes; D004149:Dioxoles / Q000494:pharmacology*; D005650:Fumarates / Q000378:metabolism; D007295:Inositol Phosphates / Q000378:metabolism; D017705:Lignans; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D009247:NADH, NADPH Oxidoreductases / Q000378:metabolism; D019255:NADPH Oxidases; D009504:Neutrophils / Q000187:drug effects* / Q000378:metabolism; D010101:Oxygen Consumption / Q000187:drug effects; D010936:Plant Extracts / Q000494:pharmacology; D010946:Plants, Medicinal; D051381:Rats; D017207:Rats, Sprague-Dawley; D016897:Respiratory Burst / Q000187:drug effects*; D013481:Superoxides / Q000378:metabolism
D034242:Cyclooctanes; D004149:Dioxoles; D005650:Fumarates; D007295:Inositol Phosphates; D017705:Lignans; D010936:Plant Extracts; D013481:Superoxides; C005998:dihydroxyfumarate; D009240:N-Formylmethionine Leucyl-Phenylalanine; C034557:schizandrer A; D000242:Cyclic AMP; D009247:NADH, NADPH Oxidoreductases; D019255:NADPH Oxidases; D002118:Calcium